Topamax (Topiramate): Clinical Overview
FDA-Approved Indications
Topamax is FDA-approved for three primary indications: epilepsy monotherapy (≥2 years), epilepsy adjunctive therapy (≥2 years), and migraine prophylaxis (adults) 1. Additionally, topiramate combined with phentermine is approved for weight loss in patients with BMI >30 1.
Epilepsy Indications (Detailed)
- Monotherapy: Initial treatment for partial onset or primary generalized tonic-clonic seizures in patients ≥2 years 1
- Adjunctive therapy: For partial onset seizures, primary generalized tonic-clonic seizures, and Lennox-Gastaut syndrome in patients ≥2 years 1
Migraine Prophylaxis
- Approved for prophylaxis of migraine headache in adults 1
Dosing Regimens
Epilepsy Monotherapy
Adults and pediatric patients ≥10 years:
- Initial dose: 50 mg/day in two divided doses 1
- Titration: Increase weekly by 50 mg increments for first 4 weeks, then 100 mg increments for weeks 5-6 1
- Target dose: 400 mg/day in two divided doses 1
Children 2 to <10 years:
- Initial dose: 25 mg/day administered nightly for first week 1
- Titration: Over 5-7 weeks 1
- Target dose: Weight-based daily doses in two divided doses 1
Epilepsy Adjunctive Therapy
Adults with partial onset seizures or Lennox-Gastaut syndrome:
- Initial dose: 25-50 mg/day 1
- Titration: Increase weekly by 25-50 mg increments 1
- Target dose: 200-400 mg/day in two divided doses 1
Adults with primary generalized tonic-clonic seizures:
Pediatric patients:
- Initial dose: 25 mg/day (or 1-3 mg/kg/day) nightly for first week 1
- Titration: Increase at 1-2 week intervals by 1-3 mg/kg/day in two divided doses 1
- Target dose: 5-9 mg/kg/day in two divided doses 1
Migraine Prophylaxis
Adults:
- Initial dose: 25 mg/day administered nightly for first week 1
- Titration: Increase weekly by 25 mg increments 1
- Target dose: 100 mg/day in two divided doses 1
Contraindications
There are no absolute contraindications listed in the FDA label 1.
Warnings and Precautions (Critical Safety Issues)
Acute Myopia and Secondary Angle Closure Glaucoma
Discontinue topiramate as rapidly as possible if this occurs - untreated elevated intraocular pressure can lead to permanent visual loss 1.
Metabolic Acidosis
- Baseline and periodic serum bicarbonate measurement is recommended 1
- Consider dose reduction or discontinuation if clinically appropriate 1
- Avoid use with other carbonic anhydrase inhibitors, drugs causing metabolic acidosis, or ketogenic diets 1
Oligohidrosis and Hyperthermia
Monitor for decreased sweating and increased body temperature, especially in pediatric patients 1.
Fetal Toxicity
Topiramate use during pregnancy can cause cleft lip and/or palate 1. This is a critical consideration for women of childbearing age.
Cognitive/Neuropsychiatric Effects
- May cause cognitive dysfunction, psychomotor slowing, difficulty with memory and concentration 1
- Patients should use caution when operating machinery including automobiles 1
- Depression and mood problems may occur 1
Suicidal Behavior and Ideation
Antiepileptic drugs, including topiramate, increase the risk of suicidal behavior or ideation 1.
Hyperammonemia and Encephalopathy
- Can occur with or without concomitant valproic acid use 1
- Measure ammonia if encephalopathic symptoms occur 1
- Patients with inborn errors of metabolism or reduced mitochondrial activity have increased risk 1
Hypothermia
Has been reported with and without hyperammonemia during topiramate treatment with concomitant valproic acid use 1.
Kidney Stones
Risk is increased; avoid use with other carbonic anhydrase inhibitors 1.
Withdrawal Considerations
Withdrawal of topiramate should be done gradually 1.
Adverse Effects
Most Common Adverse Effects (≥5% more than placebo)
In epilepsy trials:
- Paresthesia
- Anorexia
- Weight decrease
- Fatigue
- Dizziness
- Somnolence
- Nervousness
- Psychomotor slowing
- Difficulty with memory
- Difficulty with concentration/attention
- Cognitive problems
- Confusion
- Mood problems
- Fever
- Infection
- Flushing 1
In migraine trials:
- Paresthesia
- Taste perversion 1
Discontinuation Rates Due to Adverse Events
Epilepsy monotherapy (adults):
- Approximately 14% of pediatric patients in the 400 mg/day group discontinued 1
- Most common reasons: difficulty with concentration/attention, fever, flushing, confusion 1
Epilepsy adjunctive therapy:
- 11% of adults receiving 200-400 mg/day discontinued 1
- 28% of adults receiving 200-1,600 mg/day in clinical studies discontinued 1
- Most common reasons: psychomotor slowing (4.0%), difficulty with memory (3.2%), fatigue (3.2%), confusion (3.1%), somnolence (3.2%) 1
Drug Interactions
Antiepileptic Drug Interactions
Key interactions from FDA label 1:
| AED Co-administered | Effect on AED Concentration | Effect on Topiramate Concentration |
|---|---|---|
| Phenytoin | No change or 25% increase* | 48% decrease |
| Carbamazepine | No change | 40% decrease |
| Valproic acid | 11% decrease | 14% decrease |
| Lamotrigine | No change (at TPM ≤400 mg/day) | 13% decrease |
*Plasma concentration increased 25% in some patients, generally those on twice-daily phenytoin dosing 1.
Oral Contraceptives
Decreased contraceptive efficacy and increased breakthrough bleeding should be considered, especially at doses >200 mg/day 1.
Clinical Efficacy Evidence
Epilepsy Monotherapy
In controlled trials, topiramate 1,000 mg/day demonstrated superior efficacy compared to 100 mg/day: 50% responder rate was 46% vs 13%, and 13% achieved 100% seizure reduction vs 0% 2. Time to exit was significantly longer with higher doses 2.
Migraine Prophylaxis
Topiramate 100-200 mg/day significantly reduced monthly migraine frequency compared to placebo (reduction from 5.4-5.6 to 3.3 migraines/month vs 5.6 to 4.6 with placebo, p<0.001) 3. Responder rates (≥50% reduction) were 54.0% and 52.3% for 100 and 200 mg/day respectively, vs 22.6% for placebo 3.
For chronic migraine, topiramate 100 mg/day reduced migraine/migrainous headache days by 6.4 vs 4.7 with placebo (p=0.010) 4.
Common Clinical Pitfalls
- Titration too rapid: The current recommended slower titration improves tolerability compared to earlier clinical trials 1
- Inadequate monitoring: Failure to monitor serum bicarbonate for metabolic acidosis 1
- Contraceptive counseling: Not warning patients about reduced oral contraceptive efficacy at doses >200 mg/day 1
- Abrupt discontinuation: Always taper gradually to avoid seizure exacerbation 1
- Ignoring cognitive effects: Patients must be counseled about operating machinery and driving 1